Marfan syndrome (MFS) is an autosomal dominant disease that affects the skeletal, ocular and cardiovascular systems. Defects in the gene that codes for fibrillin (FBN-1) are responsible for MFS. Here we report the world's first use of preimplantation genetic testing (PGT) to achieve a clinical pregnancy and live birth of a baby free of a Marfan mutation. One or two blastomeres from each embryo were tested for a CA repeat within the FBN-1 gene. The prospective mother is homozygous for the CA repeat (2/2) and has two normal copies of the FBN-1 gene, while the prospective father is heterozygous for the CA repeat (1/2), and is affected with the Marfan syndrome. In the father's family, allele 2 segregates with the mutated FBN-1 gene. For PGT, any embryo diagnosed as heterozygous for the CA repeat (1/2) would be presumed to have inherited normal FBN-1 genes from the father and the mother and be unaffected. One in-vitro fertilization (IVF) cycle yielded 12 embryos for preimplantation testing; six of the embryos were heterozygous for the CA repeat (1/2) and presumed to be free of the Marfan mutation. Five of the six embryos were subsequently transferred into the uterus. The fetus was tested by chorionic villus sampling and found to be free of the Marfan mutation by the same linkage analysis, had a normal fetal echocardiogram, and was normal at birth.
Introduction
Marfan syndrome (MFS) is a disease of the connective tissues, and is inherited in an autosomal dominant fashion. MFS affects approximately 1 in 10 000 people (Dietz et al, 1993) . Manifestations of MFS include pectus deformity, arachnodactyly, scoliosis, high and narrow palate, ectopia lentis, myopia, dilation of the ascending aorta, aortic dissection, mitral valve abnormality, and dural ectasia (Pyeritz, 1993) . The clinical features of MFS arise from a lack of normal fibrillin, a structural constituent of connective tissue. The underlying defect in MFS is due to a defective fibrillin gene (FBN-1) which has been localized to chromosome 15q [15] [16] [17] [18] [19] [20] [21] (Leeetal., 1991).
Preimplantation genetic testing (PGT) of in-vitro fertilized (IVF) embryos offers prospective parents who carry genetic disorders the chance to conceive children of their own with a greatly reduced risk of transmission of the disease (Harper and Handyside, 1994; Levinson et al, 1995) . Until now, patients affected with MFS have not had this opportunity. Their only option was prenatal genetic testing (analysis of fetal cells after amniocentesis or chorionic villus sampling), followed by possible termination of the pregnancy if the fetus was carrying the mutation. In this report, we describe a preimplantation genetic testing cycle to obtain embryos free of the Marfan syndrome mutation.
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Materials and methods
Patient history
The prospective mother was 35 years old, gravida 1, parity 0. Her husband was affected with the Marfan syndrome. His sister had a sudden aortic dissection at age 32, and his father, who was also affected, died at 34 years of age. The patient's previous pregnancy was terminated after prenatal linkage analysis revealed that the fetus had a mutated FBN-1 allele.
The prospective mother and father had a distinguishable complement of alleles at the CA repeat within FBN-1 (Figure 1 ). The prospective mother was homozygous (2/2) at this locus, while the prospective father was heterozygous (1/2). Allele 2 segregated with MFS in the father's family. Any embryo that exhibited a heterozygous complement at this locus (1/2) would be free of the MFS mutation.
IVF and embryo biopsy IVF stimulation and oocyte retrieval were as previously described (Levinson et al., 1995) . A total of 17 eggs were retrieved, of which 16 were viable. Each viable egg was inseminated in a microdroplet under oil with ~2500 spermatozoa 6 h after retrieval. In all, 12 dividing embryos developed, and were biopsied as previously described (Levinson et al, 1992) . 
Procedure
Each individual blastomere was removed from the surrounding medium using a silanized 20 fj. 1 Unopette (Fisher Scientific, Pittsburgh, PA, USA), and washed two times in 5% fetal bovine serum/phosphatebuffered saline (FBS/PBS) (Life Technologies Inc., Gaithersburg, MD, USA) at room temperature. After two washes, the blastomere was transferred in 1-2 (il of 5% FBS/PBS to a labelled 0.5 ml silanized polymerase chain reaction (PCR) tube containing 5 (0. 1 of Lysis Mix I using a different silanized Unopette. Samples were covered with two drops of mineral oil (Sigma Chemical Co., St. Louis, MO, USA), and incubated at 65°C for 10 min, followed by immediate incubation at 95°C for 10 min. Each sample was then allowed to cool to room temperature while all other samples were being processed. PCR Mix I (44 (j.1) was then added to each sample, under the oil. The samples were held at 85°C prior to the next step (-10 min). Samples were then thermocycled (Perkin Elmer Cetus, Foster City, CA, USA) as follows: initial denaturation, 94°C, 4 min, followed by four cycles of denaturation at 94°C, 2 min, annealing at 56°C, 1 min, and extension at 72°C, 1 min 30 s, followed by 31 cycles as above but with denaturation shortened to 1 min, followed by a final extension of 72°C for 5 min.
Second round PCR for FBN-l was performed by adding 1 (il of first round PCR product to 49 |il PCR Mix II, covering with two drops of mineral oil and thermocycling with initial denaturation of 94°C, 4 min, followed by 35 cycles of denaturation at 94°C, 1 min, annealing at 60°C, 1 min, and extension at 72°C, 1 min 30 s, followed by final extension of 72°C for 5 min.
PCR primers for gender were multiplexed with FBN-l primers as an internal control for PCR of single cells. Separate second rounds were performed for amelogenin X and amelogenin Y, as well as for DYZ1, as previously described (Levinson el al., 1992 (Levinson el al., , 1995 .
PCR products from FBN-l primer sets were visualized by denaturing polyacrylamide gel electrophoresis using 5% Long Ranger™ modified acrylamide (FMC Bioproducts, Rockland, ME, USA) prepared with urea (Life Technologies) per manufacturer's instructions. One volume of second round PCR product was mixed with two volumes of formamide/EDTA Stop Solution (US Biochemicals, Cleveland, OH, USA), heated to 95°C for 5 min and then held at 72°C prior to loading on the gel. The gel was prewarmed at 80 W constant power for 30 min prior to loading 6 |il/ lane. To aid in determining the size of PCR products, a G lane from an M13mpl8 sequencing reaction (US Biochemical) labelled with [ 33 S]-dATP (NEN Dupont) was run, as well as second round PCR products from maternal and paternal DNAs as gel controls. Gels were run at 80 W constant power for 2000 volt-hours, vacuum dried at 80°C without fixation, and autoradiographed with XAR-5 film (Kodak, Rochester, NY, USA) for 30 min to 1 h at room temperature.
Results
By ~72 h after retrieval, 12 embryos had divided and were biopsied at the 3-10-cell stage. For added reliability, two blastomeres were removed from all embryos except the 3-cell embryo (from which only one blastomere was removed), and analysed in separate PCR reaction tubes. Six embryos were determined to be heterozygous (1/2) for the CA repeat (Table I) . The patients elected to transfer five of the six presumably unaffected embryos (Figure 2) . A healthy 8 pound, 11 ounce male was delivered vaginally at term. His physical examination was normal. Testing by chorionic villus sampling had confirmed that the fetus did not inherit the MFS allele, and a fetal echocardiogram had also been normal. All other embryos were cryopreserved.
Discussion
We report the first clinical use of PGT to avoid a child affected with the Marfan syndrome. The method of linkage analysis should be applicable to this and other diseases for which a direct test is not available, providing that: (i) linkage phase can be rigorously determined from the DNA of relatives who are known carriers; (ii) sufficient polymorphism exists to allow the investigator to clearly distinguish maternal and paternal markers such as CA repeats; and (iii) the linkage markers allow robust nested amplification from a single cell.
The importance of internal PCR controls in each reaction and the use of more than one blastomere from each embryo, whenever possible, can be seen in Table I . Our laboratory uses both of these steps to try to eliminate any possibility of contamination from exogenous DNA or cellular material in our PCR reactions for PGT. Any contamination from outside the PCR tube could result in a misdiagnosis of an affected embryo as a normal embryo and lead to an affected baby being bom. Embryos that have conflicting PCR results are not recommended for transfer.
Allelic dropout (failure to detect an allele which may result from competition between two alleles for reagents in the PCR tube) is another important problem for PGT of autosomal dominant diseases. The diagnostic system must be tested rigorously before a patient is cycled to determine the frequency of allelic dropout for single cell assays. In the present case, allelic dropout of the normal allele would lead to nonreplacement of an unaffected embryo, but not to the misdiagnosis of an affected embryo as normal.
Because of phenotypic variability, lack of a genetic or biochemical test for the disease, and a high rate of sporadic disease, the actual incidence of the Marfan syndrome may be considerably higher than the reported 1 in 10 000 (Dietz et al., 1993) . With growing awareness of and research on the Marfan syndrome and the present case experience, the clinical demand for a reliable PGT is likely to increase.
